SunPharma和Cipla回忆了美国制造缺陷的药物,其健康风险从低到中。 Sun Pharma and Cipla recall U.S. drugs over manufacturing flaws, with low-to-moderate health risks.

由于制造问题,Sun Pharma和Cipla召回了几个美国药物。 Sun Pharma and Cipla have recalled several U.S. drugs due to manufacturing issues. Sun Pharma正在召回24 600多瓶Frococinolone Acetonide 局部溶液和某些Clindamycin 磷酸盐分批物,原因是杂质和降解测试失败,这两类产品都指出健康风险较低。 Sun Pharma is recalling over 24,600 bottles of Fluocinolone Acetonide Topical Solution and certain Clindamycin Phosphate batches for failing impurity and degradation tests, both Class III recalls indicating low health risk. 美国Cipla公司正在召回15221个兰胺注射针,原因是颗粒物,这是一个可能对健康产生暂时影响的II类召回. Cipla USA is recalling 15,221 Lanreotide Injection syringes due to particulate matter, a Class II recall with potential for temporary health effects. 召回计划于2025年底和2026年初启动,反映了美国食品和药物管理局对美国市场药品质量的持续监督. The recalls, initiated in late 2025 and early 2026, reflect ongoing FDA oversight of drug quality in the U.S. market.